论文部分内容阅读
目的探讨以吡喃阿霉素（THP）为主联合化疗方案治疗晚期食管瘤的临床疗效。方法从1994年4月～1997年12月，共有88例病人按TDF（THP、DDP、5－FU）方案进行治疗。结果取得了CR15例（17．05％），PR49例（55．68％），有效率（CR＋PR）为72．25％；远期随访半年生存率为92．04％，1年生存率为51．11％，2年生存率为20．45％，3年生存率为5．6％。结论以THP为主的联合化疗方案为治疗晚期食管瘤较好的治疗方案，且毒副反应较同类产品阿霉素（ADM）低。
Objective To investigate the clinical efficacy of pramirromycin (THP) combined chemotherapy regimen in the treatment of advanced esophageal tumors. Methods From April 1994 to December 1997, a total of 88 patients were treated with TDF (THP, DDP, 5-FU) regimens. Results 15 cases (17.05%) of CR, 49 cases (55.68%) of PR were obtained, and the effective rate (CR+PR) was 72.25%; the long-term follow-up six-year survival rate was 92.04%, and the 1-year survival rate was 51 In .11%, the 2-year survival rate was 20.45%, and the 3-year survival rate was 5.6%. Conclusions THP-based combination chemotherapy is a better treatment option for the treatment of advanced esophageal tumors, and its toxicity is lower than that of doxorubicin (ADM).